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Summary.-The binding of human immunoglobulin to Type C viruses has been
analysed by radioimmunoassay. The assay is a double-antibody, solid-phase RIA,
which has been optimized and calibrated using rabbit and human anti-MuLV sera.
It detects varying concentrations of IgG binding to HL-23-V-1, a human Type C
virus isolate, in all of a large number of human sera tested. As judged by inhibition
with nonspecific glycoproteins, heterophile antigens and pure saccharides, this
binding is to the glycoside moiety of the virus-envelope glycoproteins, in agreement
with other recent reports. Nonspecific binding of this type stringently restricts the
interpretation which can be placed on these and earlier data in man concerning
antibodies to Type C viruses. It does not however exclude the possibility that Type C
viruses do occur in man and do elicit antibody therein.
SERO-EPIDEMIOLOGY providesimportant
clues to the possible activity of oncogenic
viruses in man. It is largely on this basis
that Epstein-Barr virus has been identi-
fied, not only as the cause of infectious
mononucleosis (Niederman et al., 1970)
but also as a likely cause of Burkitt's
lymphoma (de The et al., 1978) and naso-
pharyngeal carcinoma (Henle & Henle,
1976). This type of evidence has also been
important in detecting endogenous and
exogenous Type C virus activity in
animals (Charman et al., 1975; Jhle et al.,
1976; Nowinski & Kaehler, 1974). Any
claim for serological evidence of Type C
virus in man (Kurth et al., 1977) therefore
deserves careful scrutiny.
The widespread presence ofanti-Type C
virus antibodies in the human population
(healthy and cancer patients) has been
described (Aoki et al., 1976; Caldwell et al.,
1975: Kurth et al., 1977; Kurth &
Mikschy, 1978; Loui et al., 1976; Snyder
et al., 1976), but also questioned (Gardner
et al., 1977; Krakower & Aaronson, 1978:
Stephenson & Aaronson, 1976). In the
absence of a Type C virus of indisputable
origin, proteins from well characterized
mammalian Type C viruses have been
used in the above studies. As most ofthese
viruses are immunologically and bio-
chemically similar, it was hoped that a
putative human virus would follow the
same pattern. The discrepancies between
the reports have been ascribed to the use
of different techniques, viral antigens and
serum samples (Kurth et al., 1977; Kurth
& Mikschy, 1978). Moreover, the speci-
ficity of these antibodies has been ques-
tioned (Hogg et al., 1979; Snyder et al.,
1976).
A further investigation ofthe occurrence
and specificity of antibodies to these
viruses in man has accordingly been car-
ried out. This started with the aim of
carrying out sero-epidemiology, but de-
veloped into a critical study of the
specificity of the antibodies involved. The
virus chosen as the basis for the assay was
HL-23V-1 virus, isolated from a human
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leukaemic cell line (Gallagher & Gallo,
1975) and known to be similar to non-
human primate viruses (Chan et al., 1976;
Okabe et al., 1976; Teich et al., 1975). Sera
were also tested for reactivity to murine
Moloney leukaemia virus (M-MuLV) and
to avian virus, the Prague strain of Rous
sarcoma virus (RSV) Subgroup A. A
simplified double-antibody solid-phase
radioimmunoassay was developed and
standardized. Binding activity was de-
tected in a large number ofnormal human
sera. Inhibition studies indicate that this
binding was directed at the carbohydrates
of viral glycoproteins, and was non-
specific in character. These findings have
been reported in abstract (Russell et al.,
1979). Similar conclusions have been
reached in recent studies using radio-
immuno-precipitation rather than solid-
phase assays (Barbacid et al., 1980;
Snyder & Fleissner, 1980).
METHODS
The following cell lines were used: NIH/
3T3, mouse fibroblast; NRK, rat kidney;
KNRK, NRK transformed by murine sarc-
oma virus (MSV) Kirsten strain; 1OK,
KNRK infected with HL-23V-1 (Teich et al.,
1975); 7605L, human diploid fibroblasts; XC
(Svoboda, 1960; Rowe et al., 1970). Cells were
routinely grown in Dulbecco's modification
of Eagle's medium supplemented with 10%
foetal calf serum (FCS).
HL-23V-1 and the Moloney strain ofmouse
leukaemia virus (M-MuLV) were pelleted
respectively from supernatants of 1OK and
NIH/3T3 (M-MuLV-infected) cell lines and
then purified in sucrose-density gradients.
The-Prague strain ofRous sarcoma virus Sub-
group A (RSV) was purified from super-
natant of virus-infected chicken embryo
fibroblast culture. This medium was supple-
mented with 10% tryptose phosphate broth,
1% chicken serum and 1% FCS. Feline
leukaemia virus (FeLV-A/F422) produced
from a cell line derived from a cat lymphoma,
was received from Dr 0. Jarrett (Glasgow).
After dialysis against phosphate-buffered
saline (PBS), viral protein concentration was
determined by the Lowry method and the
viruses kept in aliquots at - 70°C.
Proteins were obtained from the following
sources: tetanus toxiod, Wellcome Labora-
tories; ribonucleases A and B, Sigma; fetuin
and 0x2-macroglobulin, Dr J. Ivanyi (Well-
come Laboratories); HL-23V-gp7O and p30
were prepared in guanidine HCl, and gp7O
was further purified by lentil lectin chromato-
graphy; bovine (Fraction V) (BSA), Sigma;
human serum albumin (HSA crystallized),
Miles. Monosaccharides were purchased from
Sigma.
Human sera were collected from normal
volunteers or supplied by Dr R. Kurth
(Friedrich - Miescher - Laboratorium, Max-
Planck-Institute, Tubingen, West Germany)
and Dr F. Katz (St Bartholomew's Hospital,
London). Sera from terminal cancer patients
immunized against murine Rauscher leuk-
aemia virus (R-MuLV) and respective pre-
immune samples were kindly supplied by Dr
E. M. Hersh (M.D. Anderson Hospital,
Houston, Texas) (Hersh et al., 1974).
Rabbit anti-HL-23V-1 and anti-M-MuLV
were prepared by s.c. injection of 400 ,ug of
virus protein in complete Freund's adjuvant,
followed by 200 ,ug of protein in incomplete
Freund's adjuvant at 3 weekly intervals.
Rabbit anti-Ig antibodies were purified by
affinity chromatography. Antibodies and
viruses were labelled by the chloramine T
method (Greenwood et al., 1963).
In the binding assay, virus was first dis-
rupted by freezing and thawing x 10. To each
well of a flexible polyvinyl chloride "U"
microtitration plate (Cooke) 1 jtg of viral
protein in 50 Jul of PBS was added. After
adsorbing overnight at room temperature the
plates were washed in PBS and used or
stored at -70°C. Before use, to minimize
nonspecific binding, wells were filled with
100 jil of 4% human serum albumin (HSA,
chosen because this protein does not com-
petitively inhibit binding) in PBS and incu-
bated for 1 h at 37°C. The plates were washed
again and 50 ,ul of the antiserum dilutions in
2% HSA were added in triplicate and incu-
bated for 1 h at 37°C, or overnight at 4°C, as
indicated. After further washing, the plates
were incubated for 1 h at 37°C with 50 ,ul/well
of 1251-labelled anti-Ig antibody (16 ng) in
2% HSA. After final washing, wells were cut
out and counted in a gamma counter. The
figures show specific binding, given by sub-
tracting the background binding to wells not
coated with antigen from the binding in the
presence of antigen. Titres are given by the
inverse of the dilution giving 50% of the
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maximumIi binidiuig ofthe labelled second anti-
body. At the 5000 end point the assay detects
150 ng of purified antibody/ml of serum.
In order to test for cross-reactivity between
positive human sera and rabbit anti-viral
sera, virus-coated plates w,ere preincubated
for 1 h either wNith first human then rabbit
serum, or vice versa. Competition was carried
out by pre-incubating sera at their 5000 end-
point with increasing dilutions of antigen or
monosaccharides. Incubation was carried out
in microtubes at 4°C for 3 h, or as indicated,
and NAas slightly higher at this than at room
temnperature. After centrifugation the stan-
dard binding assay was performed. Maximunm
binding was given by the unabsorbed samples.
WA'hen human sera were tested for the pres-
ence of antigen(s) Ig was removed from sera
by affinity chromatography.
Neutralization ofHL-23V-1 infectivity was
measured by the XC cell cytopathogenicity
assay (Rowe et al., 1970) using the cell line
7605L as the infected cell. Forty PFU of
HL-23V-1 virus were incubated for 1 h at
37°C wtith serial 2-fold dilutions of the test
serum. The serum titre was determined as the
dilution giving 5000 reduction in plaque
number.
For absorption experiments, cultured cells
w%rere prepared by removal from bottles with
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a rubber policeman. Cells cultured in human
sera were always passaged x 3 before absorp-
tion. The absorptions were done in the pro-
portion of 1 vol packed x 3 washed cells/3 vol
serum at 37°C for 1 h, with graded numbers
of cells where indicated.
The viral proteins which bound to human
antibodies were purified by affinity chromato-
graphy. The eluted proteins were then run in
a 10% SDS-acrylamide gel and stained with
Coomassie blue.
RESULTS
Representative titration curves are
shown in Fig. 1 for the binding of various
human immunoglobulins to HL-23V-1.
The curves are in parallel for (i) serum
from a representative normal donor, (ii)
pooled normal IgG, and (iii) anti-R-
MuLV serum of human origin. All 97
human sera tested were positive, with a
range of titre from 1: 8 to 1: 588. Titres in
about the same range were obtained for
binding to M-MuLV (data not shown). The
titres could not be related to the condition
of the serum donors. In the neutralization
assay, none of the human sera neutralized
0 5 1 0 20 40 80 1 60 320 640 1 280
Reciprocal serum dilution
_ , , , , T~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
2.16 1.08 0.54 0.27 0.135 0.0375 0.01875 0.009375 0.0046875 0.0046875
Imneunoglobulin dilution (mg/ml)
FIG. ].--Titration curves of lhuman sera and immutnoglobulins on HL-23V-1 virus-adsorbed plates.
0 Normal serum (No. 20). O PooledC normal IgG. O) Anti R-MuLV serum.
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HL-23V-1 at a dilution of 1: 2, while a
control rabbit antiserum to the virus
neutralized at I :8000.
Free HL-23V-1 competitively inhibited
binding of normal human Ig, with minor
variations between individual sera (Fig.
2a). So did M-MuLV with selected normal
human serum, and to a lesser e.xtent so did
RSV, but not a control protein, tetanus
toxoid (Fig. 2b). A variety of glyco-
proteins and sera were then tested for
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competitive activity with selected normal
human sera: BSA, fetuin, a2-macroglobu-
lin and purified gp7O of HL-23V-1 proved
active (e.g. 2%o BSA gave 18%o inhibition)
and only HSA was inactive, as would be
expected from the design of the assay.
Other non-glycosylated proteins, besides
tetanus toxoid and ribonucleases A and B,
proved inactive, as did purified p30 of
HL-23V-1. FCS and normal rabbit serum
were both active, inhibiting by 44-5900
at a concentration of 500o. Reversing the
assay, HL-23V-1 proved able to block the
binding of human Igs to x2-macroglobulin
adsorbed on to plates.
Intact cells were next examined for com-
petitive activity. The mouse and rat cell
lines could all absorb activity from
selected normal human Igs, but not from
rabbit anti-HL-23V-1 serum. In order to
evaluate the importance ofmaterial picked
up from the medium, cells were grown in
media containing either FCS or in human
serum selected for low reactivity towards
HL-23V-1. KNRK cells grown under
either condition removed all binding
activity, whilst human 7605L cells,
whether grown in FCS, human serum, or
infected with HL-23V-1, did not remove
the activity significantly (Fig. 3). KNRK
cells and uninfected 7605L cells removed
little activity from rabbit anti-HL-23V-1;
7605L cells infected with HL-23V-1 did
absorb, as expected. Thus cell membranes
bear intrinsic antigens which can absorb
FIG. 2.-(a) Viral competition for human
antibody binding to HL-23V- 1 virus-a(l-
sorbed plates. Disrupted HL-23V-1 was
used as competitive antigen. To tubes con-
taining increasing amounts of HL-23V- 1,
the amount of human serum necessary to
hiave a final dilution corresponding to its
500/ end-point was added. The mixture
was incubatedl for 3 1i at 4°C, centrifuge(d
and the assays carried out on ice. S.e. +
60%. 0 Normal human sample 65. 0 Nor-
mal hiuman sample 63. U Normal human
sample 60. (b) Viral competition immtuno-
assays for human serum sample 65antibo(dy
binding to HL-23V-l virus using disrupted
HL-23V-1 (0), M-MuLV (O) and RSV (*)
viruses, or tetanus toxoict (A) as comp6ti-
tive antigens. Assays performed as in (a).
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the binding activity from normal human
Ig but not from anti-viral antibody. This
clearly distinguishes between the speci-
ficity of the 2 types of Ig, and suggests
that the normal human Igs are binding to
heterophile antigens. In conformity with
the heterophile-binding hypothesis, human
(Blood Group A, AB, 0), hamster, sheep,
chicken and rabbit, but not human or
chicken erythrocytes could absorb to vary-
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ing extents (data not shown). The effec-
tiveness of the competition shown by
glycoproteins strongly suggested that
carbohydrate determinants are involved.
Sera at a dilution representing 50%0 of
maximum binding, were therefore incu-
bated with monosaccharides. Out of 11
sugars tested, 3 (N-acetyl-D-galactos-
amine, D-galactose and methyl-D-manno-
pyranoside) were able to lower the binding
by a further 50%0 at concentration of
15-8 mM, whilst 8 (N-acetyl-D-mannos-
amine, N-acetyl-D-mannose, D-glucose,
D4 + mannose, N-acetyl-D-glucosamine,
L- and D-fiucose, D-glucosamine. HCI and
90
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Fioa. 3. (a) Absorption of human serum
sample 63 with KNRK cells. Absorptions
were performed as described in Methods,
centrifuged and titrated for residual activ-
ity in HL-23V-1 virus-adsorbed plates. 0
Unabsorbed serum. A Absorbed with
KNRK cells cultured in presence of FCS.
O Absorbed with KNRK cells cultured in
presence ofhumain serum. (b) Absorption of
lhuman serum sample 63 withi 7605L htuman
cell line. Absorption and titration as in (a).
O Unabsorbed serum. C- Absorbed with
7605L cells cultured in presence of FCS. e
Absorbed with 7605L cells cultured in pres-
ence of human serum. e Absorbed with
7605L cells infected with HL-23V-1 an(d
cultured in presence of FCS. (c) Absoiption
of rabbit anti-HL-23V-1 serum with 7605L
and KNRK cell lines. Absorption anci titra-
tion as in (a). 0 Uroabsorbed serum. O
Absorbed with 7605L cells culltured in pres-
ence of FCS. 0 Absorbed with 7605L cells
infected with HL-23V-1 aind cuiltured in the
presence of FCS. A Absorbed with KNRK
cells cultured in presence of FCS.
I I I I I I I I I
5 10 20 40 80 160 320 640 1280
Reciprocal serum dilution
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with virus-specific proteins, corresponding
to viral gp7O (Fig. 5). This agrees with the
competitive capacity demonstrated by
this protein. Three additional weaker
bands could be seen, 1 barely entering the
10 20 40 80 160 320 640 1280
Reciprocal serum dilution
FIG. 4. Hyperimmune rabbit anti-HL-23V-1
serum in competition with human serum for
viral antigenic sites.
0 Virus-adsorbed plates were incubated
with the rabbit immune serum (1: 40) for 60
min at 37°C. After washing, human serum
(sample 60) was titrated. * Human serum
titration curve in the absence of pre-
incubation with anti-HL-23V-1 serum.
OZ2-rhamnose) were not. In one experiment
performed with U2-macroglobuhin-adsorbed
plates, and the same serum end-point
dilution, a mixture of the 3 above-
mentioned sugars showed an adsorption
of 80% at a concentration of 2 mm.
In further confirmation of the distinc-
tion in specificity between normal human
serum and rabbit anti-HL-2VI serum, the
2 types of serum did not compete with one
another in binding to virus (Fig. 4).
In an attempt to identify further the
viral components to which normal human
Ig bind, virus eluted from sepharose-
bound pooled human Ig were run in 10%
acrylamide gel. Only one band co-migrated
FIG. 5. SDS-acrylamide-gel electrophoresis
of viral stock proteins binding to naturally
occurring human antibodies. A, virus pro-
teins purified in immunoabsorbent columns
preparedwith humani Ig. B, HL-23V-I viral
stock proteins. C, HL-23V-1 gp7O and p30
purified proteilns. D, Standard proteins:
BSA (68K), ovalbumin (45K), carbonic
anhydrase (29K), ribonuclease (13-7K).
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FiG. 6.-Effect of absorptioni of lbuman anti-
R-1lItLV seirium (E37) and pre-immuine
serum (E30) witb KNRK or rabbit red
cells. Absorptions were (lone as indicate(l in
AMethods for 60 min at 37°C. (a) After cen-
trifugation, the sera were assayed for re-
maining activity on HL-23V-1 virtus-ad-
soirbedI plates. Immune serum: 0 Unab-
sorbed. O Absorbe(d withi rabbit red cells. A
Absorbed w%ith KNRK cells. Pre-immuine
serum: * Unabsorbed. * Absorbed with
KNRK cells. 0 Absorbed wlith rabbit recl
cells. (b) After absorptioin, sera were assayed
on MF-MuLV virus-adsorbed plates.
gel and 2 with mol. wts of 64,000 and
60,000 respectively.
Several bleedings of 2 patients immun-
. ized with R-MuLV (Hersh et al., 1974;
Charman et al., 1975) were tested in the
< assay, with similar results (Fig. 6). The
reactivity of the immune serum at the
50% end-point when tested on M-MuLV
plates, is reduced to 86% after absorption
U' with rabbit red cells and by a further 700
to 7900 after absorption with KNRK cells.
When tested using HL-23V-1 plates the
reactivity at the 50% end-point was re-
K duced to 3000 after absorptions with
KNRK or rabbit red cells. The residual
reactivity may reflect cross-reactivity
# between HL-23V-1 and R-MuLV due to
interspecific determinants. Alternatively,
it may be a consequence of the presence
of Kirsten murine sarcoma virus in the
HL-23V-1 stock (Teich et al., 1975). The
binding ofthe pre-immune serum virtually
disappears in both cases after asbsorption.
DISCUSSION
A solid-phase radioimmunoassay has
been developed for the analysis of anti-
bodies to Type C virusus. The assay is easy
to perform, as it avoids the handling of
large numbers of tubes. It proved to be
sensitive, precise and specific.
Using this assay, Ig binding to the
human retrovirus HL-23V-1 were de-
tected in all ofa large series ofhuman sera.
As judged by inhibition with isolated
viral proteins, and by analysis of viral
proteins binding to immobilized Ig, the
binding is directed mainly at the envelope
glycoprotein gp7O. In this respect our
findings confirm earlier reports (Kurth et
al., 1977; Kurth & Mikschy, 1978). Our
interpretation of this binding is, however,
very difficult, and conforms with that
offered in more recent work (Barbacid et
al., 1980; Snyder & Fleissner, 1980). As
judged by competitive inhibition in the
assay, binding activity has the following
distribution: (i) diverse glycoproteins
(fetuin, Ac2-macroglobulin, BSA, as well as
FCS and normal rabbit serum) are posi-
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tive, but not non-glycosylated proteins
(tetanus toxoid, ribonuclease A and B);
(ii) mouse and rat cell lines are positive,
but not as a result of picking up glyco-
proteins from their growth medium; (iii)
various mammalian erythrocytes are posi-
tive, but not avian ones; (iv) human
serum proteins and a human cell line are
negative, as would be expected using Ig
of human origin; and (v) certain mono-
saccharides at high concentrations are
positive. This is precisely the distribution
expected of Ig showing heterophile bind-
ing, i.e. binding to various carbohydrate
groups present on cell membranes (Burger,
1971) and probably mainly as a result of
immunization with bacterial cell-wall anti-
gens. This hypothesis receives further sup-
port from our findings, again based on
inhibition, that the specificities in normal
human sera and immune anti-viral sera
are distinct.
This is not the first time that serologists
have been misled by cross-reactions by
carbohydrate-binding antibodies. Rabbit
antisera to fish Igs were thought initially
to detect a T-cell receptor, but upon
further analysis turned out to be directed
at carbohydrate determinants (Yamaga
et al., 1977).
Our conclusions agree with those of
Barbacid et al. (1980) and Snyder &
Fleissner (1980). We think it important to
provide data based on a solid-phase assay,
which avoids the criteria devolved at
precipitation assays. The problem of
trapping irrelevant proteins in the immune
complexes at high serum concentrations
(Charman & Gilden, 1978) does not apply
here. Thus, solid-phase assays should be
useful in any futuire search for truly virus-
specific antibody.
The possibility that man is a non-
responder to Type C viral proteins can be
eliminated. In this study sera obtained
from individuals before and after vaccina-
tion with Rauscher-MuLV were tested for
reactivity to Moloney MuLV, which shares
antigenicity with R-MuLV7. Both pre- and
post-vaccination sera contained antibodies
of the type detected in the rest of this
report. However, after removal of this
reactivity by absorption with either
KNRK cells or rabbit red cells, detectable
anti-Moloney viral antibodies remained
in post-vaccination sera but not in the pre-
vaccination sera (Fig. 6). Thus, man is
able to respond specifically to Type C
virus if brought into contact with it, and
this humoral response can be detected in
the radioimmunoassay used in this study.
We therefore conclude that the immuno-
globulin present in human serum which
binds to retroviruses is anti-carbohydrate
in nature, poorly specific, and cannot be
taken as evidence of retrovirus infection.
This work was in part supported by a scholar.ship
from the Lady Tata AMemorial Truist.
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